- Benign breast disease
- Preoperative thinning of the endometrium before hysteroscopic endometrial ablation.
Dosage & Administration
- Adult: 400-800 mg daily, in up to 4 divided doses for 3-6 week.
Benign breast disorders:
- Adult: Initially, 100-400 mg daily in 2 divided doses adjusted according to response and continued for 3-6 month.
- Adult: Initially, 200 mg bid-tid reduced thereafter according to patient’s response.
- Adult: 200-800 mg daily in 2 divided doses adjusted according to response, for 3-6 month or if necessary, up to 9 month.
- Adult: 200 mg once daily. Review treatment 3 month later.
- Adult: Male adolescents: Initially, 200 mg daily, may increase to 400 mg daily after 2 month if no response occurs; adult men: Initial: 400 mg daily in up to 4 divided doses. Usual treatment duration: 6 month.
- Child: Male adolescents: Initially, 200 mg daily increased to 400 mg after 2 month if no response occurs. Treatment usually up to 6 months.
Estrogens and progestogens: Theoretically danazol may interact with exogenous estrogens and/or progestogens. It has been suggested that danazol acts by binding to estrogen, progesterone or androgen receptors at various levels in the hypothalamic pituitary-ovarian axis. Therefore, women of child bearing age should use effective, non hormonal methods of contraception.
Anticonvulsant therapy: Danazol may affect the plasma concentration of carbamazepin and possibly the patient’s response to this agent and to phenytoin. A similar interaction is possible for phenobarbital.
Antihypertensive therapy: Danazol can oppose the action of antihypertensive agents, possibly through effects on fluid retention.
Cyclosporine: Danazol can increase the plasma concentration of cyclosporine.
Migraine therapy: Danazol itself may provoke migraine and it may possibly reduce the effectiveness of medication to prevent the condition.
- Pregnancy and breast-feeding
- Impaired hepatic, renal, or cardiac function
- Thromboembolic disease
- Androgen-dependent tumor
- Abnormal vaginal bleeding that has not been fully investigated.
- Hypersensitivity to danazol.